Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR)

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 163-168

  Santoro, Marcos Leite ^a   Ota, Vanessa Kiyomi ^a   Stilhano, Roberta Sessa ^a   Silva, Patrícia Natália ^a   Santos, Camila Maurício ^a   Diana, Mariana Cepollaro ^a   Gadelha, Ary ^a   Bressan, Rodrigo Affonseca ^a   Melaragno, Maria Isabel ^a   Han, Sang Won ^a   Abílio, Vanessa Costhek ^a   Belangero, Sintia Iole ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic; Brs3; DNA methylation; Drd2; Drd3; Gabrr1; Galr3; Gene expression; Glra1; Spontaneously hypertensive rats

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOMBESIN RECEPTOR 3 GENE; CHOLINERGIC RECEPTOR NICOTINIC GAMMA GENE; CONTROLLED STUDY; DNA METHYLATION; DOPAMINE RECEPTOR 2 GENE; DOPAMINE RECEPTOR 3 GENE; DOWN REGULATION; GABA A RECEPTOR RHO1 GENE; GENE; GENE EXPRESSION; GLYCINE RECEPTOR SUBUNIT ALPHA1 GENE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROMOTER REGION; RAT; SCHIZOPHRENIA; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISEASE MODELS, ANIMAL; DNA METHYLATION; GENE EXPRESSION; HALOPERIDOL; MALE; NEUROTRANSMITTER AGENTS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROMOTER REGIONS, GENETIC; RATS, INBRED SHR; RISPERIDONE; SCHIZOPHRENIA;

EID: 84904132473     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.015     Document Type: Article

References (60)

1. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40(7):827-834.
2. Baldessarini R.J., Tarazi F.I. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv. Rev. Psychiatry 1996, 3(6):301-325.
3. Bock C., Reither S., Mikeska T., Paulsen M., Walter J., Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005, 21(21):4067-4068.
4. Bressan R.A., Erlandsson K., Stone J.M., Mulligan R.S., Krystal J.H., Ell P.J., Pilowsky L.S. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol. Psychiatry 2005, 58(1):41-46.
5. Calzavara M.B., Medrano W.A., Levin R., Kameda S.R., Andersen M.L., Tufik S., Silva R.H., Frussa-Filho R., Abilio V.C. Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?. Schizophr. Bull. 2009, 35(4):748-759.
6. Calzavara M.B., Levin R., Medrano W.A., Almeida V., Sampaio A.P., Barone L.C., Frussa-Filho R., Abilio V.C. Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats. Behav. Brain Res. 2011, 225(1):15-22.
7. Calzavara M.B., Medrano W.A., Levin R., Libanio T.C., de Alencar Ribeiro R., Abilio V.C. The contextual fear conditioning deficit presented by spontaneously hypertensive rats (SHR) is not improved by mood stabilizers. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35(7):1607-1611.
8. Cannon T.D., Kaprio J., Lonnqvist J., Huttunen M., Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch. Gen. Psychiatry 1998, 55(1):67-74.
9. Cutting G.R., Lu L., O'Hara B.F., Kasch L.M., Montrose-Rafizadeh C., Donovan D.M., Shimada S., Antonarakis S.E., Guggino W.B., Uhl G.R., et al. Cloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(7):2673-2677.
10. Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(36):13614-13619.
11. Elliott-Hunt C.R., Pope R.J., Vanderplank P., Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J. Neurochem. 2007, 100(3):780-789.
12. Gerner R.H., van Kammen D.P., Ninan P.T. Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals. Prog. Neuropsychopharmacol. Biol. Psychiatry 1985, 9(1):73-82.
13. Girgenti M.J., Nisenbaum L.K., Bymaster F., Terwilliger R., Duman R.S., Newton S.S. Antipsychotic-induced gene regulation in multiple brain regions. J. Neurochem. 2010, 113(1):175-187.
14. Gladkevich A., Kauffman H.F., Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(3):559-576.
15. Grenningloh G., Schmieden V., Schofield P.R., Seeburg P.H., Siddique T., Mohandas T.K., Becker C.M., Betz H. Alpha subunit variants of the human glycine receptor: primary structures, functional expression and chromosomal localization of the corresponding genes. EMBO J. 1990, 9(3):771-776.
16. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011, 17(2):112-120.
17. Heresco-Levy U. N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int. J. Neuropsychopharmacol. 2000, 3(3):243-258.
18. Holmes F.E., Mahoney S., King V.R., Bacon A., Kerr N.C., Pachnis V., Curtis R., Priestley J.V., Wynick D. Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(21):11563-11568.
19. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
20. Hsu L.L., Yu J.R., Upp J.R., Glass E.J., Townsend C.M. Chronic bombesin treatment increased the [3H]spiperone binding, glutamate decarboxylase and choline acetyltransferase activity in the rat brain. Brain Res. 1987, 417(2):232-238.
21. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., Fuchs S. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(2):625-628.
22. Javitt D.C. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr. Opin. Drug. Discov. Devel. 2009, 12(4):468-478.
23. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62(6):617-627.
24. Kwak Y.T., Koo M.S., Choi C.H., Sunwoo I. Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med. Genet. 2001, 2:3.
25. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 1999, 13(4):358-371.
26. Levin R., Calzavara M.B., Santos C.M., Medrano W.A., Niigaki S.T., Abilio V.C. Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(7):1748-1752.
27. Li L.C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11):1427-1431.
28. Lopez-Munoz F., Alamo C. Neurobiological background for the development of new drugs in schizophrenia. Clin. Neuropharmacol. 2011, 34(3):111-126.
29. Lynch J.W. Native glycine receptor subtypes and their physiological roles. Neuropharmacology 2009, 56(1):303-309.
30. McCoy L., Richfield E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett. 1996, 213(2):137-141.
31. McNamara R.K., Levant B., Taylor B., Ahlbrand R., Liu Y., Sullivan J.R., Stanford K., Richtand N.M. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. Neuroscience 2006, 143(1):141-153.
32. Melas P.A., Rogdaki M., Osby U., Schalling M., Lavebratt C., Ekstrom T.J. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 2012, 26(6):2712-2718.
33. Meller C.A., Henriques J.A., Schwartsmann G., Roesler R. The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice. Peptides 2004, 25(4):585-588.
34. Nakamichi Y., Wada E., Aoki K., Ohara-Imaizumi M., Kikuta T., Nishiwaki C., Matsushima S., Watanabe T., Wada K., Nagamatsu S. Functions of pancreatic beta cells and adipocytes in bombesin receptor subtype-3-deficient mice. Biochem. Biophys. Res. Commun. 2004, 318(3):698-703.
35. Ohki-Hamazaki H., Watase K., Yamamoto K., Ogura H., Yamano M., Yamada K., Maeno H., Imaki J., Kikuyama S., Wada E., Wada K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 1997, 390(6656):165-169.
36. Olincy A., Leonard S., Young D.A., Sullivan B., Freedman R. Decreased bombesin peptide response to cigarette smoking in schizophrenia. Neuropsychopharmacology 1999, 20(1):52-59.
37. Padin J.F., Rodriguez M.A., Dominguez E., Dopeso-Reyes I.G., Buceta M., Cano E., Sotelo E., Brea J., Caruncho H.J., Isabel Cadavid M., Castro M., Isabel Loza M. Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology 2006, 51(4):923-932.
38. Papa M., Berger D.F., Sagvolden T., Sergeant J.A., Sadile A.G. A quantitative cytochrome oxidase mapping study, cross-regional and neurobehavioural correlations in the anterior forebrain of an animal model of Attention Deficit Hyperactivity Disorder. Behav. Brain Res. 1998, 94(1):197-211.
39. Paxinos G., C.W. The Rat Brain Stereotaxic Coordinates 1998, Academic Press, Sidney. 4 edition.
40. Pidsley R., Mill J. Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research. Biol. Psychiatry 2011, 69(2):146-156.
41. Roth B.L., Hanizavareh S.M., Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 2004, 174(1):17-24.
42. Russell V.A. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Behav. Brain Res. 2002, 130(1-2):191-196.
43. Saar K., Mazarati A.M., Mahlapuu R., Hallnemo G., Soomets U., Kilk K., Hellberg S., Pooga M., Tolf B.R., Shi T.S., Hokfelt T., Wasterlain C., Bartfai T., Langel U. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(10):7136-7141.
44. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci. Biobehav. Rev. 2000, 24(1):31-39.
45. Schotte A., Janssen P.F., Megens A.A., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993, 631(2):191-202.
46. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1(2):133-152.
47. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002, 47(1):27-38.
48. Sequeira P.A., Martin M.V., Vawter M.P. The first decade and beyond of transcriptional profiling in schizophrenia. Neurobiol. Dis. 2012, 45(1):23-36.
49. Siegmund K.D., Connor C.M., Campan M., Long T.I., Weisenberger D.J., Biniszkiewicz D., Jaenisch R., Laird P.W., Akbarian S. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2007, 2(9):e895.
50. Sokoloff P., Giros B., Martres M.P., Andrieux M., Besancon R., Pilon C., Bouthenet M.L., Souil E., Schwartz J.C. Localization and function of the D3 dopamine receptor. Arzneimittelforschung 1992, 42(2A):224-230.
51. Stephens S.H., Logel J., Barton A., Franks A., Schultz J., Short M., Dickenson J., James B., Fingerlin T.E., Wagner B., Hodgkinson C., Graw S., Ross R.G., Freedman R., Leonard S. Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr. Res. 2009, 109(1-3):102-112.
52. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hokfelt T., Wolinsky T.D., Konkel M.J., Chen H., Zhong H., Walker M.W., Craig D.A., Gerald C.P., Branchek T.A. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(48):17489-17494.
53. Takahashi M., Hayashi H., Watanabe Y., Sawamura K., Fukui N., Watanabe J., Kitajima T., Yamanouchi Y., Iwata N., Mizukami K., Hori T., Shimoda K., Ujike H., Ozaki N., Iijima K., Takemura K., Aoshima H., Someya T. Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr. Res. 2010, 119(1-3):210-218.
54. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 2001, 297(2):711-717.
55. Theisen F.M., Haberhausen M., Firnges M.A., Gregory P., Reinders J.H., Remschmidt H., Hebebrand J., Antel J. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007, 7(4):275-281.
56. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57(3):237-245.
57. Wang K.S., Liu X.F., Aragam N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. Schizophr. Res. 2010, 124(1-3):192-199.
58. Weber H.C. Regulation and signaling of human bombesin receptors and their biological effects. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16(1):66-71.
59. Yamada K., Ohki-Hamazaki H., Wada K. Differential effects of social isolation upon body weight, food consumption, and responsiveness to novel and social environment in bombesin receptor subtype-3 (BRS-3) deficient mice. Physiol. Behav. 2000, 68(4):555-561.
60. Zini S., Roisin M.P., Langel U., Bartfai T., Ben-Ari Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 1993, 245(1):1-7.